# Ticagrelor Administered as Standard Tablet or Orodispersible Formulation

Study · id `cardio:ct-nct03822377` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03822377](<https://clinicaltrials.gov/study/NCT03822377>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03822377

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 130 participants.

## Technical summary

Registry record NCT03822377. Randomized; single masking; primary purpose treatment. Start 2019-06-27 (actual); primary completion 2020-08-31 (actual). Results posted on 2021-09-08.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 130 participants (enrolled count; ClinicalTrials.gov record NCT03822377, source copy `cardio:ctgov-nct03822377-2021-09-08`, retrieved 2026-10-26)
- Started: 2019-06-27 (actual) (ClinicalTrials.gov record NCT03822377, source copy `cardio:ctgov-nct03822377-2021-09-08`, retrieved 2026-10-26)
- Primary completion: 2020-08-31 (actual) (ClinicalTrials.gov record NCT03822377, source copy `cardio:ctgov-nct03822377-2021-09-08`, retrieved 2026-10-26)
- Completion: 2020-08-31 (actual) (ClinicalTrials.gov record NCT03822377, source copy `cardio:ctgov-nct03822377-2021-09-08`, retrieved 2026-10-26)
- Results first posted: 2021-09-08 (ClinicalTrials.gov record NCT03822377, source copy `cardio:ctgov-nct03822377-2021-09-08`, retrieved 2026-10-26)
- Countries: Italy (ClinicalTrials.gov record NCT03822377, source copy `cardio:ctgov-nct03822377-2021-09-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03822377-2021-09-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Ticagrelor Administered as Standard Tablet or Orodispersible Formulation
- Acronym: TASTER
- Condition: ST Elevation Myocardial Infarction
- Condition: NSTEMI - Non-ST Segment Elevation MI
- Intervention (Drug): Ticagrelor orodispersible tablets
- Intervention (Drug): Ticagrelor standard tablets
- Lead sponsor: Azienda Ospedaliero Universitaria di Sassari
- Lead sponsor class: OTHER
- Collaborator: AstraZeneca
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: Non-ST-elevation heart attack (NSTEMI) (`cardio:nstemi`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry lists this organization as a collaborator: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: 24bace948360710ad78237ca84189f3b4ed54d46fca5423509c311a967472fd3
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
